PolarityTE Inc., a biotechnology company developing and commercializing regenerative tissue products and biomaterials, has released data from studies looking at its SkinTE™ product for closure of diabetic foot ulcers (DFUs) and venous stasis leg ulcers (VLUs) within a 12-week period.

SkinTE is designed to regenerate full-thickness, functional skin for the repair, reconstruction and replacement of a patient’s own skin.

The first study included wound closure rates for 11 DFU patients with Wagner 1 and Wagner 2 wounds, while the second study included wound closure rates for five VLU patients, the company said.

The chronic wounds in 10 of the 11 patients with DFUs and all five VLU patients demonstrated granulation, progressive epithelialization and closure within 12 weeks following a single application of SkinTE, PolarityTE executives said.

“Chronic lower extremity wounds, including DFUs and VLUs, represent an increasing and challenging burden on the healthcare system,” said Nikolai Sopko, M.D., Ph.D, Chief Scientific Officer of PolarityTE. “Even when combined with advanced wound therapy, they are often some of the most difficult wounds to treat using the standard of care. Consequently, these studies are important in establishing SkinTE as a treatment option for patients with chronic wounds that don’t respond well to current treatment standards.”